ARMP Armata Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 921114 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-135.9%
TTM EPS YoY-151.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-127.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets306.1%
Debt / equity—
Current ratio0.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-96.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $23.72M | $34.43M |
| SG&A expense | $12.41M | $13.18M |
| Operating income | -$36.63M | -$42.44M |
| Pretax income | -$173.80M | -$18.92M |
| Net income | -$173.80M | -$18.92M |
| EBITDA | -$35.10M | -$41.11M |
| EPS (basic) | -4.80 | -0.52 |
| EPS (diluted) | -4.80 | -0.89 |
| Weighted avg. shares (diluted) | 36.24M | 59.06M |
| Balance sheet | ||
| Cash & equivalents | $8.69M | $14.77M |
| Current assets | $10.67M | $11.31M |
| PP&E, net | $12.19M | $13.24M |
| Goodwill | $3.49M | $3.49M |
| Intangibles | $10.26M | $10.26M |
| Total assets | $76.88M | $86.44M |
| Current liabilities | $8.95M | $48.25M |
| Total liabilities | $295.48M | $134.46M |
| Shareholders' equity | -$218.60M | -$48.02M |
| Shares outstanding | 36.43M | 36.18M |
| Cash flow statement | ||
| Operating cash flow | -$25.76M | -$37.55M |
| Capital expenditure | $542,000 | $1.88M |
| Free cash flow | -$26.30M | -$39.43M |
| Investing cash flow | -$542,000 | -$1.88M |
| Financing cash flow | $25.61M | $34.96M |
| Depreciation & amortization | $1.53M | $1.32M |
| Stock-based compensation | $2.61M | $2.89M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.